Embecta (Nasdaq:EMBC) announced today that its board of directors elected the company’s CEO, Devdatt “Dev” Kurdikar, as chair.
The Parsippany, New Jersey-based BD Diabetes spinoff also named Dr. Claire Pomeroy as lead independent director. Both appointments go into effect immediately. These changes follow the retirement of David Melcher, who previously served as non-executive chair of the board.
Kurdikar joined BD in 2021 to join the company’s diabetes care business, overseeing it during its separation from the medtech giant. He assumed the role of president and CEO of Embecta following the 2022 spin-off, also joining the company’s board.
Changes come atop the company’s board as Embecta works through brand transition program through a phased plan to create value and shift priorities toward broader medical applications.
“Through the combined efforts of our employees around the world, Embecta has come a long way since our launch as an independent company nearly four years ago,” said Kurdikar. “I am honored that my fellow board members have placed their faith in me to continue to drive this progress while leading our transformation into a more broad-based medical supplies company.”
Read more about Embecta and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Pomeroy joined Embecta’s board of directors at its inception in 2022. In addition to serving as lead independent director, she will continue to chair the board’s Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee.
Other roles for Pomeroy include president of the Albert and Mary Lasker Foundation, a private foundation. It seeks to improve health by accelerating support for medical research through research excellence, public education and advocacy.
Pomeroy also serves as a director of Haemonetics and on a number of other boards across several foundations, centers, labs, schools and more.
“I wish to thank the board for their trust and support as we work together to carry out Embecta’s mission to empower people with diabetes today while paving the way for a life unlimited for all,” said Pomeroy. “Between Dev’s leadership and our board’s diversity of experience and shared sense of purpose, I have great confidence in our ability to advance embecta’s transformation and long-term success.”
